Stage 3 proposed rule on the way

Brace yourselves. The proposed rule for Meaningful Use Stage 3 has been sent to the Office of Management and Budget and will be posted in the Federal Register once the office completes their review, according to a spokesperson for the Centers for Medicare & Medicaid Services (CMS).

“We are proposing the Stage 3 criteria that EPs, eligible hospitals and [critical access hospitals (CAHs)] must meet in order to successfully demonstrate Meaningful Use under the Medicare and Medicaid EHR Incentive Programs, focusing on advanced use of EHR technology to promote improved outcomes for patients,” states the Department of Health and Human Services in their submission to OMB. “Stage 3 will also propose changes to the reporting period, timelines and structure of the program, including providing a single definition of Meaningful Use. These changes will provide a flexible, yet, clearer framework to ensure future sustainability of the EHR program and reduce confusion stemming from multiple stage requirements.”

HHS also said it is working with CMS and the Office of the National Coordinator for Health IT to “ensure that the Stage 3 Meaningful Use definition coordinates with the standards and certification requirements being proposed and that there is sufficient time to upgrade and implement these changes.”

Back in March, the Health IT Policy Committee approved recommendations to HHS on criteria for Stage 3, which included 19 objectives for providers to comply with rather than the 26 in an earlier version. The committee aimed to tighten the focus of Stage 3, reduce the burden on providers and rely on available and mature standards. During listening sessions held in May, however, stakeholders said the Stage 3 recommendations were still too broad.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.